EJHaem · 2025
Outcomes for Patients With Myeloid Neoplasms Treated With Chemotherapy Plus Venetoclax After Prior Venetoclax Therapy.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Madero-Marroquin Rafael, Cannova Joseph, Dworkin Emily, Wesevich Austin, Roloff Gregory W, Saygin Caner, Nawas Mariam T, DuVall Adam S, Kosuri Satyajit, Thirman Michael J, Odenike Olatoyosi, Stock Wendy, Larson Richard A, Drazer Michael W, Patel Anand A
Аннотация
BACKGROUND: Outcomes for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that have progression after treatment with hypomethylating agent (HMA) and venetoclax (VEN) are poor. However, data for chemotherapy and VEN (C+VEN) therapy after prior treatment with HMA+VEN are limited.
METHODS: We identified 18 patients with AML or MDS/AML who received C+VEN after prior HMA+VEN.
RESULTS: Complete remission (CR) or CR with incomplete hematologic recovery (CRi) was achieved in 7 patients (39%) and 6 patients (33%) proceeded to allogeneic hematopoietic stem cell transplantation.
CONCLUSION: This study shows suggests that C+VEN could be a viable option in a subset of patients after HMA+VEN.
METHODS: We identified 18 patients with AML or MDS/AML who received C+VEN after prior HMA+VEN.
RESULTS: Complete remission (CR) or CR with incomplete hematologic recovery (CRi) was achieved in 7 patients (39%) and 6 patients (33%) proceeded to allogeneic hematopoietic stem cell transplantation.
CONCLUSION: This study shows suggests that C+VEN could be a viable option in a subset of patients after HMA+VEN.